Home » Stocks » GMAB

Genmab A/S (GMAB)

Stock Price: $31.24 USD -0.51 (-1.61%)
Updated Mar 8, 2021 4:00 PM EST - Market closed
After-hours: $31.23 -0.01 (-0.03%) Mar 8, 6:42 PM
Market Cap 20.02B
Revenue (ttm) 800.90M
Net Income (ttm) 323.28M
Shares Out 64.30M
EPS (ttm) 0.51
PE Ratio 61.51
Forward PE 74.63
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $31.24
Previous Close $31.75
Change ($) -0.51
Change (%) -1.61%
Day's Open 31.37
Day's Range 31.02 - 31.46
Day's Volume 1,492,847
52-Week Range 16.24 - 44.83

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 21 hours ago

Company Announcement

GuruFocus - 1 day ago

Introduction

GlobeNewsWire - 1 day ago

Company Announcement

GlobeNewsWire - 6 days ago

Company Announcement

GlobeNewsWire - 6 days ago

Company Announcement

GlobeNewsWire - 1 week ago

Company Announcement

GlobeNewsWire - 1 week ago

Company Announcement

GlobeNewsWire - 1 week ago

Company Announcement

GlobeNewsWire - 1 week ago

Company Announcement

GlobeNewsWire - 1 week ago

Company Announcement

GlobeNewsWire - 1 week ago

Company Announcement

GlobeNewsWire - 2 weeks ago

Company Announcement

Investors Business Daily - 3 weeks ago

Hijacking the immune system to destroy cancer with bispecific antibodies could be a lucrative business for biotech stocks like Amgen, Genmab and Regeneron Pharmaceuticals. The post The $12 Bil...

Other stocks mentioned: AMGN, REGN
Benzinga - 3 weeks ago

Genmab (NASDAQ: GMAB) and Seagen Inc (NASDAQ: SGEN) have jointly announced the submission of a marketing application with the FDA, seeking accelerated approval for tisotumab vedotin for the tr...

GlobeNewsWire - 3 weeks ago

Company Announcement

Business Wire - 3 weeks ago

BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced the submission of a Biologics License Application (BLA) to the U...

Other stocks mentioned: SGEN
Seeking Alpha - 1 month ago

BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and p...

Other stocks mentioned: ANNX, ASA, BME, BMEZ, BST, BSTZ, GNMSF, KYMR, MASI, OSH, SGEN, SGTX, TSHA
GlobeNewsWire - 1 month ago

Company Announcement

GlobeNewsWire - 1 month ago

Company Announcement

Other stocks mentioned: GNMSF
GlobeNewsWire - 1 month ago

Company Announcement

GlobeNewsWire - 1 month ago

Company Announcement

GlobeNewsWire - 2 months ago

Media Release Copenhagen, Denmark, January 6, 2021

Zacks Investment Research - 2 months ago

Genmab (GMAB) starts the global phase III innovaTV 301 study evaluating tisotumab vedotin versus chemotherapy for treating recurrent/metastatic cervical cancer.

GlobeNewsWire - 2 months ago

Company Announcement

GlobeNewsWire - 2 months ago

Media Release COPENHAGEN, Denmark, Jan. 04, 2021

Seeking Alpha - 2 months ago

Genmab is a well-managed and vast European biopharma R&D giant. Its partnered products and self-owned pipelines are vast.

GlobeNewsWire - 2 months ago

Company Announcement

GlobeNewsWire - 2 months ago

Company Announcement

GlobeNewsWire - 3 months ago

 Janssen submitted a BLA to U.S. FDA for amivantamab for patients with non-small cell lung cancer with epidermal growth factor receptor Exon 20 insertion mutations

GuruFocus - 3 months ago

If you are looking for potential value opportunities amid U.S.-listed equities, picking stocks that meet the following three criteria represent a solid starting point, in my opinion:

Other stocks mentioned: DHI, MNST
GlobeNewsWire - 3 months ago

Company Announcement

GlobeNewsWire - 3 months ago

Company Announcement

GlobeNewsWire - 3 months ago

Media Release Copenhagen, Denmark, November 10, 2020 Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D. and CFO Anthony Pagano, will present an update at the Jeff...

GlobeNewsWire - 4 months ago

Company Announcement

GlobeNewsWire - 4 months ago

Media Release Copenhagen, Denmark, November 5, 2020

Seeking Alpha - 4 months ago

Genmab A/S (GMAB) CEO Jan van de Winkel on Q3 2020 Results - Earnings Call Transcript

Other stocks mentioned: GNMSF
GlobeNewsWire - 4 months ago

November 4, 2020; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2020

GlobeNewsWire - 4 months ago

Media Release Copenhagen, Denmark, November 4, 2020

GlobeNewsWire - 4 months ago

Media Release Copenhagen, Denmark and Lausanne, Switzerland, October 30, 2020

Other stocks mentioned: ADCT
GlobeNewsWire - 4 months ago

Company Announcement

GlobeNewsWire - 4 months ago

     Media Release Copenhagen, Denmark, October 14, 2020

GlobeNewsWire - 4 months ago

Company Announcement

Seeking Alpha - 4 months ago

Genmab: Still A Rising Star In Biotech, But Legal Dispute May Slow Down Growth Trajectory In The Near Term

GlobeNewsWire - 5 months ago

Company Announcement

GlobeNewsWire - 5 months ago

Copenhagen, Denmark; September 30, 2020 – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the...

Other stocks mentioned: GNMSF
Reuters - 5 months ago

Shares in Danish biotech firm Genmab fell as much as 14% on Wednesday after it said it was locked in a legal battle with its partner Johnson & Johnson over royalty payments for its key cancer ...

Other stocks mentioned: JNJ
GlobeNewsWire - 5 months ago

Copenhagen, Denmark; September 22, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that it has commenced binding arbitration of two matters arising under its license agreement with Janssen Bi...

Business Wire - 5 months ago

BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) and Genmab A/S (Nasdaq: GMAB) today presented data from the innovaTV 204 pivotal phase 2, single-arm...

Other stocks mentioned: SGEN
Investopedia - 5 months ago

These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.

Other stocks mentioned: INVA, MRSN, NVAX, REGN, TECH, VNDA, XBIT
GlobeNewsWire - 5 months ago

Media Release Copenhagen, Denmark, September 10, 2020

About GMAB

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovar... [Read more...]

Industry
Biotechnology
Founded
1999
CEO
Jan van de Winkel
Employees
781
Stock Exchange
NASDAQ
Ticker Symbol
GMAB
Full Company Profile

Financial Performance

In 2019, Genmab A/S's revenue was 5.37 billion, an increase of 77.39% compared to the previous year's 3.03 billion. Earnings were 2.17 billion, an increase of 47.15%.

Financial numbers in millions DKK.
Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Genmab A/S stock is "Buy." The 12-month stock price forecast is 42.43, which is an increase of 35.82% from the latest price.

Price Target
$42.43
(35.82% upside)
Analyst Consensus: Buy